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ABSTRACT 
 
Background: Patients with T cell immunodeficiencies are generally treated by 
allogeneic hematopoietic stem cell transplantation but alternatives are needed 
for patients without matched donors. An innovative intrathymic (IT) gene 
therapy approach, directly targeting the thymus, may improve outcome.  
Objective: To determine the efficacy of IT-adeno-associated virus (AAV) 
serotypes to transduce thymocyte subsets and correct the T cell 
immunodeficiency in a ZAP-70-deficient murine model. 
Methods:  AAV serotypes were injected intrathymically into WT mice and gene 
transfer efficiency was monitored.  ZAP-70-/- mice were intrathymically injected 
with an AAV8 vector harboring the ZAP-70 gene. Thymus structure, 
immunophenotyping, TCR clonotypes, T cell function, immune responses to 
transgenes and autoantibodies, vector copy number and integration were 
evaluated.   
Results: AAV 8, 9 and 10 serotypes all transduced thymocyte subsets following 
in situ gene transfer, with transduction of up to 5% of cells. IT injection of an 
AAV8-ZAP-70 vector into ZAP-70-/- mice resulted in a rapid thymocyte 
differentiation, associated with the development of a thymic medulla. Strikingly, 
medullary thymic epithelial cells expressing the autoimmune regulator AIRE 
were detected within 10 days of gene transfer, correlating with the presence of 
functional effector and regulatory T cell subsets with diverse TCR clonotypes 
in the periphery. While thymocyte reconstitution was transient, gene-corrected 
peripheral T cells, harboring approximately 1 AAV genome/ cell, persisted for 
>40 weeks and AAV vector integration was detected.  
Conclusions: Intrathymic AAV-transduced progenitors promote a rapid 
restoration of the thymus architecture with a single wave of thymopoiesis 
generating long-term peripheral T cell function.   
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Key Messages: 
• Intrathymic AAV gene correction of an immunodeficiency promotes the 
differentiation of a normal thymic architecture within 10 days post gene 
transfer  
• Intrathymic AAV gene transfer results in vector integration with the 
persistence of gene-corrected peripheral T cells for >40 weeks  
 
Capsule Summary: 
Intrathymic AAV-mediated gene therapy presents a novel therapeutic option for 
immunodeficient patients, promoting a rapid reconstitution of the thymic 
environment and subsequent T cell reconstitution.    
  
Key Words: 
Severe combined immunodeficiency, Gene therapy, ZAP-70, thymus, 
intrathymic gene transfer, medulla formation, T cell reconstitution, humoral 
immunity 
 
Abbreviations: 
AAV: adeno-associated virus 
AIRE: autoimmune regulator 
DN: double negative CD4-CD8- 
DP: double positive CD4+CD8+ 
ELISA: enzyme-linked immunosorbent assay 
GvHD: graft versus host disease 
HLA: human leukocyte antigen 
HSC: hematopoietic stem cell 
Ig: immunoglobulin 
IT: intrathymic 
IV: intravenous 
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LN: lymph node 
MFI: mean fluorescence intensity 
mTEC: medullary thymic epithelial cell 
PCR: polymerase chain reaction 
PID: primary immunodeficiency 
SCID: severe combined immunodeficiency 
SEM: standard error of the mean 
SP4: single positive CD4 
SP8: single positive CD8 
TEC: thymic epithelial cell 
TCR: T cell receptor 
Vg/Dg : vector genomes/ diploid genomes 
ZAP-70: Zeta-associated protein of 70kDa 
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INTRODUCTION 
 
Primary immunodeficiency diseases (PID) consist of a heterogeneous group of 
more than 200 genetic disorders1, with severe combined immunodeficiency 
(SCID) characterized by defective T and B lymphocyte function. 
Transplantation of histocompatible hematopoietic stem cells (HSCs) is the 
optimal treatment for infants with SCID but in the absence of histocompatible 
donors, these patients typically receive an HSC transplant from HLA-
haploidentical donors. In the latter case, T cells are extensively depleted from 
the graft in an effort to prevent graft versus host disease (GvHD).  Although 
recent modifications of this protocol have resulted in an increased survival rate, 
significant short-term and long-term complications are still reported and the lag 
time during which the patient remains susceptible to infections is quite long2.  
Thus, although this treatment is generally successful, it remains important to 
develop new therapeutic approaches. 
 
Significant efforts have gone into developing gene therapy strategies for these 
patients. Indeed, gene therapy trials for X-SCID and more recently for 
adenosine deaminase-deficiency and Wiskott-Aldrich demonstrated that this 
strategy can cure human disease and they have continued to marketing 
approval3-12. The selective advantage of corrected progenitors and the massive 
expansion of corrected T cells has facilitated this success. Adverse events due 
to insertional mutagenesis of gammaretroviral vectors13-16 have resulted in the 
development of lentiviral-based clinical trials for SCID patients.  Notably, 
mutagenesis has not been reported in the latter 5, 17, 18 but it is still important to 
continue to explore and develop new therapeutic strategies.  
 
Following transplantation of SCID patients with allogeneic healthy HSCs or 
gene-corrected autologous HSCs, T lymphocyte differentiation occurs in the 
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thymus19.  These HSCs, administered by intravenous (IV) injection, must 
continuously home to the thymus because under physiological conditions, 
thymic settling progenitors are only able to give rise to a single round of 
thymocyte differentiation20-23. Notably though, the intrathymic injection of HSCs 
as well as pro-T cells improves T cell differentiation in the thymus24-31 and 
increases the expansion of supporting thymic epithelial cells32.  Additionally, the 
thymus can be targeted by the direct injection of antigens or vectors expressing 
genes of interest33-37, with recombinant Adeno-Associated Virus (rAAV) vectors 
transducing thymocytes with a 10-fold higher efficiency than lentiviral vectors 
34,37. Indeed, rAAV vectors hold great promise for gene transfer therapies 
because they are capable of infecting non-dividing cells and particles of high 
titer and purity can be produced38-42.  
 
rAAV vectors were initially developed as single stranded viral DNA vectors. The 
transduction efficiency of these “conventional” rAAV vectors, based on the 
AAV2 serotype, is known to be tissue-dependent with significant gene transfer 
in various tissues43-48 but only low level infection of murine hematopoietic 
cells49-51. However, several AAV serotypes have exhibited increased ability to 
transduce HSCs40, 52-56 and long-term transgene persistence has been detected 
54, 55, 57.   
 
In an attempt to achieve efficient gene transfer in the thymus and correct T cell 
deficiency, we evaluated in situ intrathymic gene transfer using rAAV2 vectors 
cross-packaged into AAV 8, 9 and 10 serotypes. Intrathymic administration of 
all 3 serotypes led to transgene expression in all thymocyte subsets but AAV8 
exhibited the highest gene transfer efficiency, resulting in the transduction of 
up to 5% of all thymocytes. Using mice that are immunodeficient due to 
mutations in the ZAP-70 protein tyrosine kinase	58 as a paradigm, we found that 
the intrathymic injection of an AAV2/8-ZAP-70 vector resulted in the 
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development of gene-corrected mature thymocytes within 10 days of gene 
transfer. Concurrently, AAV8-ZAP-70 gene transfer promoted the development 
of the thymic medulla, containing AIRE-expressing medullary thymic epithelial 
cells (mTECs) that mediate T-cell tolerance.  Furthermore, AAV-transduced T 
cells were detected in the peripheral circulation by 2 weeks and these T cells 
exhibited long-term function for greater than 10 months, responding robustly to 
T cell receptor (TCR) stimulation. Thus, the thymus immune niche can be 
shaped by an intrathymic AAV-based strategy, accelerating the restoration of 
its architecture and facilitating a transient thymocyte differentiation with long 
term peripheral T cell function. 
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METHODS  
AAV vector stocks, harboring the GFP or ZAP-70 genes, were administered by 
intrathymic injection into WT C57Bl/6 mice and ZAP-70-/- mice as indicated.  All 
animal experiments were performed in accordance with the recommendations 
of the CNRS Animal Care Committee and were consistent with the guidelines 
set by the Panel on Euthanasia (AVMA) and the NIH Guide for the Care and 
Use of Laboratory Animals. T cell reconstitution was monitored by flow 
cytometry and frozen thymic sections were stained as previously described59. 
Vector genomes were monitored by real time PCR, for integration analyses, we 
adopted a sonication-based linker-mediated PCR method as previously 
described 60, 61. Anti-OVA IgG responses were evaluated following ovalbumin 
immunization, serum anti-ZAP-70 antibodies as well as anti-dsDNA, anti-RNP 
and anti-SSA antibodies were evaluated by enzyme-linked immunosorbent 
assay (ELISA), neutralizing antibodies were monitored as previously 
described62 and gene expression (Foxp3, IL-10) was evaluated by qRT-PCR. 
TCR repertoire was evaluated by deep sequencing and data analyzed using R 
Studio. Screening for IgM/IgG reactivity against autoantigens was performed 
using autoantibody arrays63, 64.   
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RESULTS 
 
Intrathymic AAV8 gene therapy reconstitutes the thymus architecture 
within 1.5 weeks and promotes a transient thymocyte differentiation  
We first assessed the potential of self-complementary rAAV2 vectors (scAAV) 
harboring the GFP transgene and pseudotyped with the 8, 9 and 10 capsid 
serotypes to transduce the murine thymus. Our analyses revealed thymocyte 
transduction by all 3 serotypes; efficiencies in non-conditioned 
immunocompetent mice ranged from 2-5% by three days post injection (Fig 1, 
A). Transduced cells were found in all subsets, including the most immature 
CD4-CD8- double negative (DN), double positive (DP) and the most mature 
single positive (SP) CD4 (SP4) and CD8 (SP8) thymocytes (Fig 1, A, B). Mice 
transduced with AAV9 vectors exhibited lower levels of DP thymocytes, within 
both the non-transduced and transduced subsets, suggesting a possible 
toxicity (Fig 1, A, B). However, total thymocyte numbers were not significantly 
altered, with a mean of 180x106/ thymus. Furthermore, in mice undergoing IT 
administration with the AAV2/8 vector, the repartition of thymocyte subsets 
remained stable (Fig 1, B).  
 
Following transduction of thymocytes, mature SP4 and SP8 thymocytes 
migrated to the periphery, strikingly representing up to 1% of peripheral T 
lymphocytes in lymphoid-replete WT mice at day 10 (Fig 1, C). However, gene-
transduced peripheral T cells decreased by 2-fold at day 30, likely due to the 
emigration of newly differentiated mature thymocytes. Given the high-level 
transduction of thymocytes by AAV8, including immature DN thymocyte 
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progenitors, we studied the potential of this serotype to correct thymocyte 
differentiation in an immunodeficient mouse model. 
 
Using a model of ZAP-70-deficient mice, exhibiting an arrest in thymocyte 
differentiation at the DP stage (reviewed in 58), we assessed whether the IT 
administration of an AAV8 vector could be used to efficiently achieve gene 
transfer in defective thymocytes.   Importantly, 3 days following IT transfer of 
the AAV2/8-GFP vector used above (Fig 1, A), the transduction of both DN and 
DP thymocytes was detected (Fig 1, D). Notably, gene transfer was detected 
in 2-5% of ZAP-70-/- thymocytes, resulting in the transduction of a mean of 
0.8x106 DN thymocytes and 4.6x106 DP thymocytes (n=11, Fig 1, D). Thus, the 
level of IT AAV8 transduction in thymocytes of ZAP-70-/- immunodeficient mice 
was similar to that detected in WT mice, supporting the utilization of this 
strategy for gene transfer.   
 
Defects in the development of SP thymocytes, irrespective of the mutation, 
result in a lack of a functional thymic medulla and it is likely that these stromal 
abnormalities contribute to immune dysregulation in the thymus (reviewed in65, 
66). Defective medulla formation is classically associated with a lack of mTECs 
expressing the autoimmune regulator (AIRE). Its absence results in an aberrant 
T-cell selection67 and the subsequent development of autoreactive T cells 
(reviewed in68, 69). Using a transgenic model, it has been shown that the leaky 
differentiation of as few as 3.5x105 non-transgenic SP4 thymocytes, bearing 
TCRs with reactivities against self-antigens, is sufficient for the formation of a 
functional medulla70. As we detected the transduction of >1x106 DN/DP 
thymocytes in ZAP-70-/- mice using an AAV8 gene transfer approach (Fig 1, E), 
we hypothesized that an IT AAV8 gene therapy strategy might promote the 
generation of sufficient SP4 thymocytes for medulla formation. We therefore 
assessed whether thymic architecture is modified by the intrathymic 
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administration of single-stranded (ss) AAV8-ZAP-70 virions (1-3x1013 vector 
genomes (vg)/kg). In the absence of gene transfer, thymi of ZAP-70-/- mice 
harbored only a minimal medulla with a mean of 115 AIRE+ cells/mm2 of tissue 
(Fig 2, A, B). Notably, within 10 days following IT AAV8-ZAP-70 gene transfer, 
there was a dramatic generation of medullary tissue and the number of AIRE+ 
mTECs significantly increased to 295/mm2 of tissue (p<0.001; Fig 2, A, B). 
While the numbers of AIRE+ cells decreased between 3 and 10 weeks post IT 
AAV8-ZAP-70 gene transfer (154/mm2 to 95/mm2), they remained significantly 
higher than those in age-matched ZAP-70-/- mice treated with control AAV8-
GFP vector (p<0.05; Fig 2, B). Moreover, medulla development was robust, 
increasing from <0.03 mm2 to 0.06 mm2 by 1.5 weeks post gene transfer 
(p<0.01, Fig E1, A). It is interesting to note that medullary area remained 
significantly elevated for the first 3 weeks post gene transfer but then decreased 
at week 10, suggesting a transient thymic reconstitution (Fig E1, A).  
 
As medulla formation and the generation of AIRE+ mTECs are dependent on a 
cross-talk with mature SP thymocytes (reviewed in65, 66,68, 69), these data 
strongly suggested that T cell differentiation proceeded rapidly following IT 
gene delivery. Furthermore, mTEC turnover is estimated at 2-3 weeks71, 72, 
suggesting that the decrease in AIRE+ cells that we observed at 10 weeks post 
gene transfer (Fig 2, B) was associated with a single wave of thymocyte 
differentiation. Indeed, within the WT thymus, the percentages of gene-
transduced cells that represented mature SP4 and SP8 thymocytes peaked at 
day 10 following gene transfer, likely representing the maturation of DP 
thymocytes27, 73, 74, and decreased by 3 weeks, consistent with SP thymocyte 
emigration75 (Fig 1, C and 2, C, p<0.01). Differentiation of SP4 and SP8 
thymocytes was detected in AAV8-ZAP-70-treated ZAP-70-/- mice but was not 
associated with a significant change in total thymocyte numbers, likely due to 
similar initial thymocyte numbers in the WT and KO mice (Fig E1, B). Notably, 
Pouzolles et al. 
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the maturation of gene-transduced SP8 thymocytes in IT AAV8-ZAP-70-
corrected ZAP-70-/- mice followed a similar kinetics to that detected in WT mice 
(Fig 2, C). SP4 thymocytes peaked even earlier, at 3 days post transduction 
(Fig 2, C, p<0.01, right panel). These data are in agreement with the kinetic 
signaling model of thymocyte differentiation wherein all DP thymocytes are first 
signaled to an intermediate SP4 thymocyte fate, before SP8 differentiation 76. 
Mature SP thymocytes were detected at all time points in WT mice, but as 
expected from the physiological involution of the thymus with age, the absolute 
numbers of SP thymocytes decreased between 0.5 (3 days) and 3 weeks post 
gene transfer (note that mice were 3 weeks of age at the time of gene transfer; 
Fig 2, D). The total numbers of SP thymocytes in ZAP-70-/- mice following 
AAV8-ZAP-70 gene transfer were greater than 2x106 at 3 days post gene 
transfer (Fig 2, D).  Consistent with the gradual loss of AIRE+ cells and the 
decreasing medulla size following IT gene correction (Fig 2, B), SP thymocytes 
decreased to baseline levels at 3 weeks (Fig 2, D). Together these data 
strongly suggest that intrathymic AAV gene correction provides for a single 
wave of thymocyte differentiation. 
 
Intrathymic AAV8-ZAP-70 transduction promotes long term maintenance 
of peripheral T cells and T lineage-specific gene transfer  
Consistent with the kinetics of thymocyte differentiation and emigration27, 73, 75, 
77, gene-corrected T cells were detected in the blood stream within 3 weeks 
following IT transfer (Fig 3, A). T cells were monitored in peripheral blood 
samples between 3 and 40 weeks post transduction. It is notable that a single 
wave of T cell differentiation allowed for the maintenance of a stable level of 
peripheral T cells for the 40 week evaluation period (>10 months).  AAV8-
ZAP70-transduced KO mice exhibited a significantly higher percentage of 
peripheral T cells relative to KO or IT:AAV8-ZAP-70 transduced KO mice at all 
Pouzolles et al. 
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time points evaluated; 3-10 weeks, 11-20 weeks, 21-30 weeks and 31-40 
weeks (p<0.0001 for all time points, Fig 3, A). 
  
The thymus is the site of T cell differentiation but B cells and hematopoietic 
progenitors with myeloid lineage potential are also present in this organ78, 79. 
Furthermore, AAV virions can diffuse, potentially resulting in the transduction 
of other cell types (reviewed in80, 81). It was therefore important to compare the 
transduction of T cells and non-T cells by AAV8-ZAP-70 virions following 
intrathymic gene transfer. As expected, almost 100% of all peripheral T cells, 
encompassing both CD4 and CD8 subsets, expressed the AAV8-encoded 
ZAP-70 transgene (Fig 3, B). Notably though, transgene expression was not 
detected in significant levels in non-T cell hematopoietic lineages, including B 
cells and myeloid cells, nor in the bone marrow during the entire 40 week follow 
up period (Fig 3, B). Furthermore, expression levels of ectopic ZAP-70 in gene-
transduced peripheral T cells were approximately 2-4-fold higher than 
endogenous levels, monitored as a function of MFI, and these levels did not 
significantly change during the 40 week follow up (Fig 3, C).  
 
We next assessed whether the maintenance of transduced T cells in the 
peripheral circulation was associated with a stable percentage and number of 
CD3+ T cells in the lymph nodes of AAV8-ZAP-70-treated mice (Fig 3, D). While 
T cell levels were significantly lower than those detected in WT mice, both in 
percentages and absolute numbers, they were induced by 3 weeks post 
intrathymic transduction, revealing the rapid initial wave of AAV-transgene-
mediated thymocyte differentiation. Furthermore, they remained stable for >10 
months. The progression of immature DP thymocytes through positive selection 
requires ZAP-70-dependent TCR signaling82,83. Positively selected DP 
thymocytes then undergo CD4/CD8 lineage choice, a complex process that has 
been shown to occur through kinetic signaling: Under conditions of persistent 
Pouzolles et al. 
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TCR signaling, CD4 T cell differentiation occurs whereas MHC-class I-specific 
CD8 T cells only differentiate following a disruption of MHC-class II/TCR signals 
and subsequent cytokine signaling84,	85. Interestingly, in the presence of high 
levels of ectopic ZAP-70 from the AAV8-ZAP-70 vector (Fig 3, C), both the 
thymic and peripheral CD4/CD8 ratios in AAV8-ZAP-70-treated mice was 
significantly skewed to a CD4 lineage fate (p<0.05; Fig 2, D and 3, E).  
 
Intrathymic AAV gene transfer results in the development of T cells with 
integrated AAV8-ZAP-70 vectors and diverse αβ T cell receptor 
clonotypes  
The persistence of gene-transduced T cells for >40 weeks was surprising in 
light of high level T cell proliferation and the propensity of AAV vectors to remain 
episomal	86. We therefore first assessed vector copy numbers in peripheral T 
cells and determined that they ranged from approximately 0.1 to 1 vector 
genomes per diploid genome (Vg/Dg), at time points ranging between 3 to 43 
weeks post intrathymic gene transfer (Fig 4, A). The low copy number 
suggested that the vector was integrated but to further assess this point, AAV8-
ZAP-70-reconstituted T cells were TCR-stimulated and copy number was 
evaluated. TCR-stimulated AAV8-ZAP-70-reconstituted T cells proliferated 
robustly, as monitored by dilution of the CTV proliferation dye, demonstrating a 
reconstituted TCR signaling cascade (Fig 4, B). Moreover, while the vast 
majority of reconstituted T cells underwent >4 divisions, AAV copy number 
(Vg/Dg) was not significantly altered, strongly pointing to vector integration (Fig 
4, B).  
 
To directly assess vector integration, genomic DNA was fragmented by 
sonication (to avoid biases caused by the non-random distribution of restriction 
sites on the genome), ligated to a barcoded linker cassette prior to PCR 
amplification, and evaluated via sonication linker-mediated (SLiM) PCR. 
Pouzolles et al. 
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Nested PCR with vector and linker cassette specific oligonucleotides allowed 
detection of PCR products with at least two different primers in LN samples 
from 3 of 6 IT:AAV8-ZAP-70-transduced mice (and 2 of 2 mice at 43 weeks 
post gene transfer; Fig 4, C).  Thus, integrated AAV is likely to be responsible 
for driving ZAP-70 expression in peripheral T cells, under conditions of long-
term persistence and TCR stimulation.     
 
The potential of differentiated T cells to recognize a large array of foreign 
proteins is fostered by the unparalleled diversity of the TCR with recombined α 
and β polypeptide chains allowing for the generation of >1015 unique 
receptors87. However, under conditions of limited thymocyte differentiation, 
repertoire diversity can be reduced34. Furthermore, infections and tumors can 
drive an antigen-mediated bias in αβ TCR repertoires (reviewed in88). While 
only few studies have monitored TCR repertoires in patients or mice treated 
with rAAV vectors, the robust T cell response against an AAV transgene in one 
trial was shown to be associated with a biased TCRBV repertoire89. It was 
therefore of important to assess the repertoire diversity in our gene corrected 
mice. As expected, the numbers of detected TRA sequences in KO as well as 
AAV8-GFP-transduced mice was minimal. However, they increased rapidly 
following ZAP-70 gene transfer (Day 10, Fig 4, D). TCR repertoire diversity was 
lower than that of WT mice but the number of distinct TRAV, TRAJ, TRBV, and 
TRBJ clonotypes increased until 3 weeks post gene transfer and remained 
stable until 43 weeks (Fig 4, D). In WT mice, clonotype distribution was not yet 
fully diverse at day 10 of life, being made up of a few mildly expanded TCRs. 
By week 3, WT mice exhibited repertoires that were fully diverse, with 1-3 
copies per clonotype (Fig 4, D, bottom). The repertoires of AAV8-ZAP-70-
reconstituted mice were less diverse than WT mice, with an expansion of some 
clonotypes, but a diverse population of TCRs was detected (Fig 4, D).     
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Induction of humoral immunity in IT-AAV8-ZAP-70-treated mice  
To determine whether AAV8-ZAP-70-tranduced mice can mount an immune 
response, mice were immunized with ovalbumin (OVA) at a late time point post 
gene transfer (46 weeks). At this time point, neither WT nor KO mice harbored 
OVA-specific antibodies. Notably though, mice that were intrathymically 
transduced with AAV8-ZAP-70 but not AAV8-GFP generated a significantly 
higher level of anti-OVA IgG antibodies by 6 weeks post immunization (1:2,000 
dilution, p<0.001, Fig 5, A). While antibody generation was lower than that 
detected in WT mice, AAV8-ZAP-70-transduced mice were already 1 year post 
gene transfer and the level of IgG generation was highly significant relative to 
KO mice (p<0.001; Fig 5, A).   
 
Changes in TCR repertoire distribution can result from immune responses 
against AAV capsid epitopes as well as the expressed transgene (reviewed 
in90). Furthermore, different rAAV serotypes have induced T-cell-dependent 
and –independent anti-capsid humoral responses91, even when injected into an 
immune-privileged organ such as the brain92. We therefore monitored the 
presence of anti-capsid antibodies in IT AAV8-treated ZAP-70-/- mice as a 
function of neutralization; neutralizing factors were defined as serum dilutions 
that inhibited AAV8 infection by >50%. No control ZAP-70-/- mice harbored 
neutralizing antibodies and at a 1/100 dilution, antibodies were not detected in 
IT AAV8-ZAP-70-treated ZAP-70-/- mice. However, at a 1/10 dilution, 10 of 14 
IT AAV8-ZAP-70-treated ZAP-70-/- mice were positive between 3 and 17 weeks 
post transduction (71%). Notably though, at this dilution, anti-AAV8 neutralizing 
activity was also detected in a high percentage of IT AAV8-GFP-treated ZAP-
70-/- mice; mice that do not have peripheral T cells (4 of 5, 80%; Fig 5, B). Thus, 
the intrathymic injection of the AAV8 serotype induces a low level T cell-
independent anti-capsid humoral response. 
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We next assessed whether the reconstituted mice exhibited an immune 
response against the ZAP-70 transgene. The intrathymic expression of the 
injected transgene likely minimizes an immune response, enhancing the 
deletion of autoreactive thymocytes33, 35, but our findings of a T cell-
independent anti-capsid neutralizing activity (Fig 5, B) suggested the possibility 
of an anti-transgene response. While anti-ZAP-70 antibodies were not detected 
at 3 weeks post AAV8-ZAP-70 transduction, 5 of 7 mice harbored antibodies at 
10 weeks (>25 ng/ml sera; p<0.01). Mean antibody levels then decreased at 
17 weeks (from 58 to 34 ng/ml) and by 43 weeks, antibody levels were 
<30ng/ml (n=5, Fig 5, C) and ZAP-70 protein did not elicit T cell activation (data 
not shown). In conclusion, anti-transgene antibodies were produced at early 
time points following intrathymic transduction but levels decreased and were 
sufficiently low that they did not result in the elimination of gene-transduced T 
lymphocytes (Fig 2, B).     
 
Patients with primary immunodeficiencies often present autoimmune 
manifestations and both immunodeficient patients and mice have been shown 
to produce a diverse range of autoantibodies64, 93. We therefore assessed 
whether gene-corrected ZAP-70-/- mice produced autoantibodies. Using an 
autoantigen microarray containing 123 different autoantigens, we did not 
observe increased levels of autoantibody production in age-matched ZAP-70-/- 
mice as compared to control mice. However, IT injections of both control AAV8-
GFP and AAV8-ZAP-70 vectors resulted in the induction of IgM antibodies 
against a broad panel of autoantigens by 3 weeks post gene transfer (Fig E2). 
IgG antibodies were significantly higher in IT AAV8-ZAP-70-transduced mice, 
in accord with the requirement of functional T cells for immunoglobulin class 
switching. IgG autoantibodies peaked at 10 weeks post transduction63, 64 (Fig 
6, A). Importantly though, absolute levels of antibodies against 3 tested 
autoantigens (double-stranded DNA (dsDNA), ribonucleoprotein (RNP), and 
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Sjögren’s-syndrome-related antigen A (SSA)) were significantly lower in AAV8-
ZAP-70-transduced mice at both 10 weeks and 43 weeks post gene transfer 
than in MRL/lpr mice which spontaneously develop a systemic lupus 
erythematosus (SLE)-like syndrome. Furthermore, levels in AAV8-ZAP-70-
transduced mice were not significantly higher than that detected in control 
MRL/MpJ mice (Fig 6, B).  Thus, intrathymic AAV8 administration induces a 
rapid but low-level, broad spectrum of autoantibodies that decreases with time. 
Notably, these low levels of autoantibodies did not result in pathological 
consequences as mice survived for over 50 weeks without overt autoimmune 
manifestations.   
 
Intrathymic AAV8-ZAP-70 gene transfer results in the differentiation of 
effector and regulatory T cell subsets 
Under conditions of lymphopenia, naive T cells proliferate in response to weak 
TCR interactions with self-peptide/MHC complexes, differentiating into 
memory-like T cells in the absence of antigenic stimulation  (reviewed in94). It 
was therefore important to study the phenotype of peripheral T cells in IT-AAV8-
ZAP-70-reconstituted mice. Notably, reconstituted mice exhibited a significant 
increase in CD62L-CD44+ effector memory T cells as compared to the majority 
of CD62L+CD44- naïve T cells in WT mice. This biased ratio of memory: naive 
T cells was detected throughout the experimental period of 10 months (Fig 7, 
A). Thus, in our study, a single wave of thymocyte differentiation following IT-
AAV8-ZAP-70 gene transfer resulted in the peripheral differentiation of 
polyclonal T lymphocytes with a memory/effector phenotype.   
 
To determine the potential effector function of AAV8-ZAP-70-transduced T 
cells, we first assessed in vivo cytokine levels. In vivo, there was a transient 
increase in TNF-α and IFN-γ levels at 3 weeks post AAV8 transduction (Fig E3, 
A), correlating with the induction of a low-level humoral response (Fig 6, A and 
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E2). However, cytokine levels then returned to baseline by 10 weeks (Fig E3, 
A), consistent with the decrease in autoantibodies. We next examined the 
ability of peripheral AAV8-ZAP70-reconstituted T cells to secrete cytokines 
upon anti-CD3/anti-CD28 mAb activation. IL-17, TNF-α and IFN-γ were 
secreted by T cells from AAV8-ZAP70-reconstituted mice by 3 weeks after 
gene transfer and secretion of all 3 cytokines was significantly higher than that 
detected in KO mice by 10 weeks (n=3-10 mice per time point, Fig 7, B; p<0.05, 
p<0.001).  As compared to WT peripheral T cells, IL-17 was the only cytokine 
that was significantly higher in gene-corrected mice (Fig 7, B; p<0.05). Thus, 
peripheral AAV8-ZAP70-reconstituted T cells were competent to secrete 
cytokines following ex vivo TCR stimulation. 
 
Despite high ex vivo TCR-induced cytokine secretion, in vivo cytokine levels 
were not elevated and AAV-reconstituted mice did not exhibit autoimmune 
symptoms. It was therefore important to assess whether gene-corrected 
regulatory T cells (Treg) controlled immune responsiveness in these mice. 
Notably, the development of Tregs expressing the Foxp3 transcription factor is 
dependent on a thymic medulla95, a structure which was restored by day 10 of 
gene transfer (Fig 2, A). Accordingly, by 3 weeks post gene transfer, Tregs 
were detected in the peripheral circulation of AAV8-ZAP-70-treated mice at 
levels similar to those in WT mice (Fig 7, C).  Notably, by 10 weeks post IT 
gene transfer, the percentages of Tregs were significantly higher in AAV8-ZAP-
70-treated mice than in WT mice (Fig 7, C; p<0.05). Importantly, these T cells 
exhibited an activated phenotype as monitored by significantly higher levels of 
Treg markers including CTLA4, GITR and CD39 (n=5 per group, Fig E3, B). As 
regards function, sorted CD4+CD25Hi cells from both WT and AAV8-ZAP-70-
transduced cells revealed equivalent levels of Foxp3 transcripts (n=12) but IL-
10 levels were significantly higher in the latter (p<0.05; Fig 7, D). Furthermore, 
IL-10 levels were significantly higher in conventional (CD4+CD25- T cells) from 
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reconstituted mice than WT mice (n=6-9; p<0.005). Thus, a high suppressive 
environment in reconstituted regulatory T cells likely restrains in vivo immune 
activation following AAV8-ZAP-70 gene transfer.    
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DISCUSSION 
 
Thymocyte development is dependent on the thymic stroma, composed of 
thymic epithelial cells (TECs) and non-epithelial cells that together form an 
organized 3-dimensional network96.  The intercellular communications between 
developing thymocytes and TECs result in a thymus architecture that allows 
the generation of a diverse and self-tolerant pool of mature T cells. In SCID 
patients as well as in cancer patients with thymus damage, an abnormal thymic 
architecture negatively impacts on thymocyte differentiation (reviewed in19, 65, 
66, 97). Here, we show that an intrathymic AAV8 gene correction results in a 
remarkable generation of mTECs and the development of a medullary 
architecture in ZAP-70-deficient mice, within 10 days of vector administration. 
Moreover, the absolute number of mTECs expressing AIRE increased by 3-fold 
in this period. AIRE is critical for immune tolerance, promoting the deletion of 
self-reactive thymocytes and the development of regulatory T cells65, 66,68, 69. 
Therefore, to date, the IT AAV gene transfer strategy described here appears 
to be the most rapid regulator of thymic architecture in immunodeficient mice. 
 
As the crosstalk between mTECs and developing thymocytes is required for T 
cell maturation, extensive research has focused on the identification of factors, 
conditions and cell types that enhance mTEC reconstitution (reviewed in98). 
The differentiation of autoreactive mature CD4 thymocytes regulates the 
formation and organization of the medulla in an antigen-dependent manner as 
shown by the importance of the CD28–CD80/86 and CD40–CD40L 
costimulatory pathways as well as RANK-RANKL and LTαβ-LTβR interactions 
(reviewed in 68). Furthermore, sex steroid ablation was found to enhance 
thymocyte differentiation by increasing Notch ligand expression on TECs99-101 
while keratinocyte growth factor (KGF), IL-22, Bmp4 and FoxN1 directly 
promote TEC proliferation and survival102-104. Specific cell types such as pro-T 
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cells facilitate thymus reconstruction32, 105, 106 while innate lymphoid cells induce 
an IL-22–mediated TEC survival107. Chemokines can also facilitate thymic 
reconstitution; under conditions of thymic damage, CCL21 treatment of 
hematopoietic progenitors rescues their migration while a combined inhibition 
of p53 and KGF increases intrathymic CCL21 expression and TEC recovery108, 
109. Notably though, the success of these approaches often requires a 
significant lag time whereas an IT AAV gene strategy corrected the medullary 
microenvironment within <10 days, concomitant with a correction of the T cell 
deficiency and the differentiation of SP4 thymocytes. It will be of interest to 
determine whether a combined approach, concomitantly correcting a T cell 
deficiency and the medullary microenvironment59, further promotes 
reconstitution. Furthermore, AAV can be used to deliver TEC-inducing 
molecules to patients suffering from suboptimal T cell differentiation––for 
example, boosting thymocyte differentiation in HSC-transplanted cancer 
patients by IT AAV administration of the IL-22 cytokine. This type of intrathymic 
targeting approach, by ultrasound-mediated guidance, has been shown to be 
minimally invasive and safe in both mice and macaques28, 31, 37, 110. Further 
studies, focused on the intrathymic administration of vectors and hematopoietic 
progenitor cells into non-human primates by interventional radiologists, will help 
to establish the clinical framework in which this type of therapeutic strategy can 
be developed.   
 
AAV vectors have successfully been used to achieve gene transfer in 
numerous tissues81. Nevertheless, studies of AAV gene transfer in the 
hematopoietic system have been more sparse, likely due to the extensive 
division of these cells. However, AAV1, modified AAV6 and AAV7 vectors have 
been found to efficiently transduce HSCs54, 57, 111, 112. Furthermore, we show 
here that AAV8, 9 and 10 serotypes promote efficient thymocyte transduction. 
While the property of AAV vector genomes to exist primarily as episomes would 
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be expected to negatively affect their ability to be used for a stable gene therapy 
in dividing cells, long-term persistence of transgene expression has been 
detected in HSCs54, 55, 57. Moreover, it has recently been shown that T 
lymphocytes represent the in vivo site of AAV persistence following natural 
infection113. This is likely linked to the AAV vector-mediated long-term 
transgene maintenance (>10 months) that we detected in gene-corrected T 
lymphocytes. Indeed, our findings that AAV vector copy number in reconstituted 
T cells was approximately 1 and that long-term reconstituted T cells harbored 
integrated vector is likely to broaden the scope of immunological deficiencies 
for which this type of approach can be envisioned. As persistence of 
intrathymic-injected progenitors with a specific T cell receptor gene provided for 
life-long immunity31, it will be of interest to determine whether the direct 
targeting of thymocytes with an AAV8-encoded tumor-specific TCR or chimeric 
antigen receptor (CAR) will promote an anti-tumor response that is superior to 
that currently achieved by ex vivo manipulation of peripheral T cells.   
    
Immune responses against AAV capsid serotypes as well as expressed 
transgenes have hampered the success of AAV gene therapy trials (reviewed 
in114). Even following AAV injections into regions that are considered to be 
immune-privileged such as the brain92 or the intravitreal space115, 116, anti-
capsid antibodies have been detected. Nevertheless, the development of 
immunosuppressive treatments has protected against AAV capsid immunity 117, 
118,119. Indeed, long-term transgene expression has been observed following 
the systemic AAV administration of genes such as myotubularin120, 121 and 
microdystrophin122, promoting AAV-based treatments for patients with X-linked 
myotubular myopathy and Duchenne muscular dystrophy, respectively.  
 
While T cell immunity can provoke anti-AAV reactivity, it can also limit 
pathological responses. The recruitment of suppressive regulatory T cells as 
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well as organ-specific T cell exhaustion can result in extended transgene 
expression123,124. While we initially hypothesized that the direct administration 
of AAV into the thymus would result in the deletion of autoreactive thymocytes 
and the subsequent absence of an immune response33, 35, we detected low 
level humoral responses to both the AAV8 capsid and the ZAP-70 transgene. 
Interestingly, anti-capsid responses were induced at similar levels in ZAP-70-/- 
mice treated by IT administration of the control AAV8-GFP vector. As T cell 
differentiation did not proceed in these latter mice, these data indicate the 
development of a T cell-independent immune response. In contrast, IgG 
autoantibodies were generated in AAV gene-corrected ZAP-70-/- mice, pointing 
to the importance of T cells in immunoglobulin class switching. Moreover, 
similarly to patients where AAV transduction correlated with increases in 
specific TCRBV families123, the humoral immune response in IT AAV8-ZAP-70-
treated mice was associated with a diverse but biased TCR repertoire. Notably 
though, the levels of generated autoantibodies were significantly lower than that 
detected in SLE-prone MRL/lpr mice and none of the IT gene therapy-treated 
mice developed symptoms of autoimmune disease during the 10 month follow 
up period. This is likely due to 1) the low and transient nature of the 
autoantibody response and 2) the extensive differentiation of AAV-corrected 
thymocytes to a Treg fate. Notably, AAV gene transfer resulted in a T 
effector/Treg ratio that allowed for a balanced immune homeostasis.  
 
Combination therapies will likely optimize life-long T cell differentiation in SCID 
patients and T cell reconstitution in cancer patients.  An ideal treatment will 
promote 1) HSC expansion, 2) the migration and entry of hematopoietic 
progenitors into the thymus 3) a thymus architecture that is conducive to 
thymocyte maturation and 4) the selection of a broad-based repertoire of self-
tolerant effector and regulatory T cells. One bottleneck is progenitor entry as 
the thymus is not continually receptive to the import of hematopoietic 
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progenitors, at least in mice125, 126. Furthermore, irradiation reduces progenitor 
homing by >10-fold109. While this bottleneck can be partially overcome by 
injecting HSCs or hematopoietic progenitors directly into the thymus24, 27, 28, 31, 
110, 127, 128, histocompatible donors are not always available. Our study reveals 
the potential of an IT AAV8 gene therapy strategy to promote an extremely 
rapid reconstitution of the thymus microenvironment and the differentiation of 
mTEC-dependent regulatory T cells within a 7-10 day period.  
 
In our studies, a single wave of thymocyte differentiation promoted the long-
term maintenance of peripheral gene-corrected T cells. Indeed, in several 
“experiments” of nature”, patients with mutations that generally result in a SCID 
phenotype were found to be relatively healthy with significant T cell numbers, 
due to a reversion mutation. As this type of event is statistically improbable, it 
is likely that the peripheral T cell reconstitution detected in these patients (with 
mutations in WAS, RAG1, LAD, NEMO, CD3zeta, gc and ADA) is due to a 
reversion mutation in a single hematopoietic progenitor129-141. While these data 
strongly support the hypothesis that gene correction of a very limited number 
of thymic progenitors can give rise to a large number of peripheral T cells, it 
remains to be determined whether T cells in these patients are due to a single 
wave of thymocyte differentiation. Moreover, in the context of an intrathymic 
gene transfer approach, it will be important to assess whether the remnant 
thymus present in many patients with SCID as well as the natural process of 
thymic involution would negatively impact on the type of therapeutic strategy 
described here. Importantly, we found that intrathymic gene transfer into Rag2-
/- mice with a remnant thymus is feasible by a surgical approach but the 
success of intrathymic HSC transfer into older mice with an involuted thymus is 
significantly reduced (our unpublished observations). Thus, a combination 
therapy of intrathymic AAV gene transfer, promoting a restoration of the thymic 
architecture and medulla formation, followed by an intravenous HSC 
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transplantation, allowing long term T cell differentiation in a reconstituted 
thymus, may presents a novel approach for the treatment of immunodeficient 
patients requiring a rapid T cell reconstitution. 
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FIGURE LEGENDS 
 
FIG 1. AAV 8, 9 and 10 serotypes efficiently transduce all thymocyte 
subsets. A, scAAV 8, 9 and 10 serotypes harboring GFP were administered 
intrathymically (IT) into WT mice and GFP expression was assessed at day 3. 
Representative CD4/CD8 profiles from non-transduced (grey) and transduced 
(green) GFP+ thymocytes are presented. B, Quantification of the percentages 
of GFP+ double negative (DN), double positive (DP), single positive CD4 (SP4) 
and single positive CD8 (SP8) thymocytes are shown and compared to non-
transduced WT mice (upper panel). Thymocyte subset repartition within non-
transduced (GFP-) and transduced (GFP+) compartments of AAV8-GFP-
transduced mice are presented (lower panel; means±SEM). C, The 
percentages of GFP+ thymocytes and lymph node (LN) T cells are presented 
as a function of time (n=3-5 mice per time point). D, Representative plots of 
GFP- and GFP+ thymocytes at day 3 following IT injection of the scAAV-GFP 
vector into ZAP-70-/- (KO) mice (left). Quantification of GFP+ cells in KO and 
AAV-transduced KO mice (n=11) are presented (top). The mean percentages 
of DN and DP thymocytes within the non-transduced (GFP-, grey) and 
transduced (GFP+, green) subsets (left bottom panel) as well as the absolute 
numbers of transduced GFP+ thymocytes are shown (right bottom panel). 
 
FIG 2. Intrathymic AAV8-ZAP-70 gene transfer results in the rapid 
reconstitution of the thymic architecture in ZAP-70-/- mice. A, ssAAV8-
ZAP-70 or scAAV8-GFP virions were IT-injected into ZAP-70-/- (KO) mice and 
thymi from WT, KO and gene-transduced mice were evaluated for the presence 
of a thymic medulla by keratin14 (K14) staining and AIRE+ cells. 
Representative confocal images of thymic tissue sections at 1.5 (10 days), 3 
and 10 weeks (w) post gene transfer are shown. B, The number of AIRE+ 
cells/mm2 of thymus were quantified in the indicated conditions. Each point 
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represents the quantification of individual medulla derived from 3 distinct mice. 
C, Mean percentages of mature SP4 and SP8 thymocytes within the 
transduced GFP+ and ZAP-70+ subsets are shown in WT (left panel) and ZAP-
70-/- (right panel) mice at the indicated time points following intrathymic AAV8-
GFP and AAV8-ZAP-70 gene transfer, respectively. D, Absolute numbers of 
SP4 and SP8 thymocytes in WT mice (left panel) and AAV8-ZAP-70-
transduced mice (right panel) were determined from the SP4 and SP8 gates at 
the indicated time points (n=5). Statistical significance was determined using 
an unpaired 2-tailed t-test or a one-way ANOVA with a Tukey’s multiple 
comparison test; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
FIG 3. Intrathymic AAV8 transduction results in long-term maintenance of 
peripheral T cells and T lineage-specific transgene expression.  A, The 
presence of peripheral blood T cells was monitored by flow cytometry following 
IT administration of AAV8-GFP or AAV8-ZAP-70 vectors and data from 
individual mice are presented at 3-43 weeks. Statistical differences between 
mice treated by IT AAV8-ZAP-70 gene transfer as compared to IT AAV8-GFP 
transfer or control KO mice were evaluated by a one-way ANOVA with a 
Tukey’s multiple comparison test for the following time groups; 3-10 weeks, 11-
20 weeks, 21-30 weeks and 31-40 weeks (***, p<0.001, for all groups).   B, The 
percentages of peripheral CD4+, CD8+, CD19+ and CD11b+ hematopoietic 
cells expressing ectopic ZAP-70 following IT AAV8-ZAP-70 transduction are 
presented. C, ZAP-70 protein expression in transduced T cells was evaluated 
by intracellular staining and MFI relative to WT T cells are presented at the 
indicated time points. D, Representative plots of CD3+ lymph node T cells are 
presented. Total T cell numbers (means±SEM) are shown (right). E, The 
repartition of CD4/CD8 lymphocytes and mean CD4/CD8 ratios are shown at 
the indicated time points. Statistical significance was determined by a 2-tailed 
unpaired t-test *, p<0.05. 
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FIG 4. AAV8-ZAP-70-transduced peripheral T lymphocytes exhibit stable 
vector genomes following TCR-induced proliferation and diverse TCR 
repertoires. A, AAV genome copy number in lymph node samples was 
assessed by qPCR in IT AAV8-ZAP-70-transduced mice at the indicated time 
points. Vector genomes per diploid genome (Vg/Dg) were quantified relative to 
the albumin gene and normalized to the percentage of T cells. B, Proliferation 
was assessed following TCR stimulation by CTV fluorescence and 
representative histograms at day 0 (light grey) and day 4 (dark grey) are shown.  
AAV genome copy was monitored as above and quantifications (n=9) are 
shown (p, non-significant (ns)). C, Schematic representation of the AAV-ZAP-
70 vector are shown. PCR products, representing integrated vector, are shown 
at the indicated time points and T cells from WT mice are presented as a 
negative control. D, The number of distinct TRA V, TRA J, TRA VJ, TRB V, 
TRB J, TRB VJ, TRA and TRB clonotypes are presented (top). Clonotype 
frequencies are presented with each clonotype represented by a dot whose 
size is proportional to its frequency. Violin plots represent the density of the 
distribution and black dots show the median frequency per repertoire (bottom).      	
 
FIG 5. Induction of a T cell-independent humoral response to AAV8 capsid 
epitopes following intrathymic vector administration. A, Total IgG titers 
against OVA were monitored in non-immunized WT, KO and IT-AAV8-ZAP-70-
treated KO mice (46w post gene transfer) and 6 weeks post immunization by 
ELISA. Reactivity was monitored as a function of dilution, as indicated (n=4). 
Statistical significance was evaluated at each dilution by a one-way ANOVA 
with a Tukey’s multiple comparison test for each dilution and is noted for 
significant differences;  ***, p<0.001; **, p<0.01. B, Neutralizing antibodies 
(Nab) against the AAV8 serotype was monitored in WT and ZAP-70-/- mice 
following intrathymic AAV8-GFP and AAV8-ZAP-70 transduction. Serum 
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dilutions of 1:10, 1:100 and 1:1000 are shown by the decreasing slope of the 
triangle, respectively, and Nab activity is defined as a decrease in AAV 
transduction of >50% compared to AAV incubation with PBS alone (red line). 
Each point represents serum from an individual mouse at 3, 10 and 17 weeks 
post transduction and mean levels are indicated by a horizontal line. C, 
Antibodies against ZAP-70 protein were measured by ELISA and data are 
presented as ng of antibody/ ml of serum. Antibody levels of >25ng/ml are 
considered significant.  
 
FIG 6. Transient induction of a broad spectrum of antibodies in ZAP-70-/- 
mice following intrathymic AAV8 gene transfer remains significantly 
lower than that detected in autoimmune mice. A, The presence of IgG 
autoantibodies in serum samples of ZAP-70-/- (KO) mice and following IT 
administration of either AAV8-GFP or AAV8-ZAP-70 vectors was evaluated at 
the indicated time points.  IgG autoantibodies against 123 antigens were 
assessed by protein microarray and heat maps showing autoantibody reactivity 
relative to levels in age-matched WT mice are presented. B, The levels of auto-
antibodies against RNP, dsDNA and SSA were evaluated by ELISA in control 
MRL/MpJ mice, autoimmune-prone MRL/lpr mice and IT:AAV8-ZAP-70-treated 
mice at 10 and 43 weeks post gene transfer. Each point represents serum from 
an individual mouse and statistical significance was determined by a one-way 
ANOVA with a Tukey’s multiple comparison test and significance is indicated; 
**, p<0.01; ***, p<0.001 ****, p<0.0001, ns-non significant.  
 
FIG 7. AAV8-ZAP-70-transduced thymocytes differentiate into effector 
and regulatory T cells. A, The presence of naïve (CD62L+CD44-, N), central 
memory (CD62L+ CD44+, CM), and effector memory (CD62L-CD44+, EM) 
cells within the CD4 and CD8 subsets were monitored at 3, 10, 17 and 43 
weeks post IT-AAV8-ZAP-70 gene transfer. The percentages of cells in each 
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subset were quantified at each time point and mean levels ± SEM (n=4-5 mice 
per time point) are presented.  B, LN cells from the indicated mice were 
stimulated ex vivo with anti-CD3/anti-CD28 mAbs for 3 days and cytokine 
secretion was measured. Each point represents data from a single mouse and 
horizontal lines represent mean levels (pg/ml). C, The percentages of 
Foxp3+CD25+ peripheral Tregs was evaluated and representative dot plots are 
presented (left) together with mean percentages ± SEM at each time point (n=5-
14 mice per time point, right). D, Conventional and regulatory CD4 T cell 
subsets were FACS-sorted on the basis of CD25 expression. Foxp3 and IL-10 
transcripts in each subset were monitored by qRT-PCR (n=2 to 4 mice in 2 
independent experiments). Statistical significance was determined by a 2-tailed 
unpaired t-test and significance is indicated; *, p<0.05; **, p<0.01; ***, p<0.001 
****, p<0.0001.   
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 MATERIALS AND METHODS 
 
rAAV constructs and vector production. The human ZAP-70 gene was 
cloned downstream of the murine phosphoglycerate kinase (PGK) promoter 
with the bovine growth hormone (BGH) polyadenylation signal sequences 
flanked by two AAV2-ITRs sequences. For the green fluorescent protein (GFP) 
coding vector plasmid, the PGK promoter is upstream of the GFP sequence 
and the simian virus 40 (SV40) polyadenylation signal. 
 
Self-complementary (sc) AAV-8, AAV-9 and AAV-10 harboring GFP and single-
stranded (ss)  AAV-8 harboring ZAP-70 vector stocks were produced by 
cotransfection of HEK293 cells with the vector plasmid and the pDG plasmid1, 
an adenoviral plasmid providing helper functions needed for rAAV assembly, 
as previously described2. Supernatants were precipitated with polyethylene 
glycol (PEG, Sigma-Aldrich) and resuspended in TBS before benzonase 
digestion. Vector-containing supernatants were purified on a double CsCl 
gradient with the first gradient centrifuged at 28,000 rpm for 24 hours at 15°C 
and the band harboring full particles was centrifuged at 38,000 rpm for 48 
hours. Viral suspensions were then subjected to 4 successive rounds of dialysis 
against DPBS in a Slide-a Lyzer cassette (Thermo Scientific). The number of 
infectious particles/ml in the purified vector prep was determined using a stable 
rep-cap HeLa cell line in a modified Replication Center Assay (RCA)3. Vectors 
were stored at <-70°C in polypropylene low-binding cryovials. 
 
Mice and intrathymic AAV gene therapy. C57Bl/6 mice ZAP-70-/- mice were 
maintained under specific pathogen-free conditions in the IGMM animal facility 
(Montpellier, France). Serum from female MRL/lpr and sex-matched control 
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MRL/MpJ mice were generously provided by Luz Blanco and Mariana Kaplan 
(NIAMS, NIH). Intrathymic injections were performed in 2.5-3 week old non-
conditioned mice with rAAV vectors (1-3x1013 vg/kg) as previously described4. 
Briefly, non-conditioned mice were anesthetized with isoflurane and vectors 
were directly injected into the thymus (20 µl total volume) by insertion of a 0.3 
ml 28 gauge 8 mm insulin syringe through the skin into the thoracic cavity above 
the sternum. All experiments were approved by the local animal facility 
institutional review board in accordance with national guidelines. 
 
Immunophenotyping, T cell activations and flow cytometry analyses. 
Cells, isolated from thymi, lymph nodes or spleen, were stained with the 
appropriate conjugated aCD3, aCD4, aCD8, aCD11b, aCD19, aCD25, 
aCD62L, aCD39, aCD44 aCTLA4 and aGITR mAbs (Becton Dickinson, San 
Diego, CA). Intracellular staining for Foxp3 and ZAP-70 was performed 
following fixation/permeabilization (eBioscience) and using the BD Biosciences 
kit, respectively. Cell activations were performed using plate-bound anti-CD3 
(clone 17A2; 1 μg/ml) and anti-CD28 (clone PV-1; 1 μg/ml) mAbs in RPMI 1640 
media (Life Technologies) supplemented with 10% FCS. Cell proliferation was 
monitored by labelling with CTV (Life Technologies; 5 μM) for 3 min at RT. 
Cytokine production was monitored using a Cytometric Bead Array (CBA) Kit 
(BD Biosciences). Stained cells were analyzed by flow cytometry (FACS-Canto 
II or LSR II-Fortessa, Becton Dickinson, San Jose, CA). Data analyses were 
performed using Diva (BD Biosciences), FlowJo Mac v.10.4.2 software (Tree 
Star) and FCAP Array Software (CBA analysis).	
 
Immunohistochemistry. Frozen thymic sections were stained as previously 
described5. Sections were stained with anti-keratin 14 (1:800; AF64, Covance 
Research) and a secondary Cy3-conjugated anti-rabbit (1:500; Invitrogen) Ab 
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together with an Alexa Fluor 488-conjugated anti-AIRE mAb (1:200; 5H12, 
eBioscience). They were then counterstained with 1 ug/ml DAPI as reported6. 
Images were acquired on a LSM 780 Zeiss and SP5 Leica confocal 
microscopes and quantified using ImageJ and Matlab software.  
Quantitative real-time PCR for evaluation of vector genomes and qRT-
PCR for cellular genes. Total DNA was extracted using the Gentra Puregene 
kit (Qiagen) and Tissue Lyser II (Qiagen) according to the manufacturer’s 
instructions. Vector genome DNAs were measured through quantification of 
BGH-pA by quantitative PCR with Premix Ex Taq kit (Takara). Primers were: 
5’-TCTAGTTGCCAGCCATCTGTTGT-3’ (forward) and 5’-
TGGGAGTGGCACCTTCCA-3’ (reverse) and the BGH-pA TaqMan probe was: 
5’-(6 FAM)-TCCCCCGTGCCTTCCTTGACC-(TAMRA)-3’. Primers for 
endogenous albumin were: 5’-ACATAGCTTGCTTCAGAACGGT-3’ (forward) 
and 5’-AGTGTCTTCATCCTGCCCTAAA-3’ (reverse). Quantitative PCR for 
BGH-pA was performed using the following program: initial denaturation 20 sec 
at 95°C followed by 45 cycles of 1 sec at 95°C and 20 sec at 60°C. qPCR for 
albumin was performed as follows: initial denaturation for 20 sec at 95°C 
followed by 45 cycles of 3 sec at 90°C and 30 sec at 60°C. For each qPCR, 
cycle threshold values (Ct) were compared with those obtained using dilutions 
of plasmids harboring either the BGH-pA or albumin genes and results are 
expressed as vector genome per diploid genome (vg/dg). 
 
For assessment of IL-10 and Foxp3 mRNA levels, CD4+CD25- and 
CD4+CD25Hi cells from WT and IT:AAV8-ZAP-70 mice (15 weeks post-
injection) were sorted on a FACSAria and RNA extraction was performed using 
the RNeasy Mini kit (Qiagen). RNA was reverse-transcribed into cDNA by 
oligonucleotide priming using the QuantiTect Reverse Transcription Kit 
(Qiagen). Each sample was amplified in triplicate (LightCycler 480, Roche) and 
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normalized to HPRT levels using the following specific primers: Foxp3-sense: 
5’-GGCCCTTCTCCAGGACAGA-3’, Foxp3-antisense: 5′-
GCTGATCATGGCTGGGTTGT-3′, IL10-sense: 5’-
AACTGCTCCACTGCCTTGCT-3’, IL10-antisense: 5’-
GGTTGCCAAGCCTTATCGGA-3’ Hprt-sense: 5′-CTGGTGAA-
AAGGACCTCTCG-3′, Hprt-antisense: 5′-
TGAAGTACTCATTATAGTCAAGGGCA-3′. 
 
Vector integration analysis. To assess AAV integration, we adopted a 
sonication-based linker-mediated PCR method, as previously described 7, 8. 
Briefly, genomic DNA was sheared using a Covaris E220 Ultrasonicator 
(Covaris Inc.), generating fragments with a target size of 1,000 bp. The 
fragmented DNA was subjected to end repair, 3’ adenylation and ligation 
(NEBNext® Ultra™ DNA Library Prep Kit for Illumina®, New England Biolabs) 
to custom linker cassettes (LC) (Integrated DNA Technologies). LC sequences 
contain: i) 8 nucleotides barcode, used for sample identification and ii) 12 
random nucleotides, used for quantification purposes. Ligation products were 
subjected to 35 cycles of exponential PCR with primers complementary to 8 
different regions of the AAV genome (see Fig 4, C and primers available upon 
request), and the LC. For each set of AAV-specific primers, the procedure was 
performed in technical replicates (n=2-3) starting from 5 to 120 ng of sheared 
DNA.  All final PCR products were quantified by qPCR using the Kapa 
Biosystems Library Quantification Kit for Illumina, following the manufacturer’s 
instructions. qPCR was performed in triplicate on each PCR product diluted 10-
3, and the concentrations were calculated by plotting the average Ct values 
against the provided standard curve, using absolute quantification. 
 
TCR Deep Sequencing and Data Processing. Cells from lymph nodes were 
pooled, lysed and RNAs extracted. T cell receptor (TCR) alpha/beta libraries 
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were prepared with 100 ng of total RNA from each sample using the SMARTer 
Mouse TCR a/b Profiling Kit from Takarabio® and sequenced by MiSeq V3 
2x300bp (Illumina®). Raw data were aligned and curated using the MiXCR 
software (v2.1.10)9. Alpha and Beta chains were analyzed together. Each 
sample was defined as a combination of TRV-CDR3aa-TRJ sequences and 
their associated counts. For representation and analyses, datasets were 
normalized by a sampling step. The sampling size was equal to the smallest 
sequence number observed in the analyzed samples (n=687). The sampling 
was performed for each dataset by 100 random draws of sequences and unique 
TCRs were listed and counted. Analyses and figures were executed and 
created using R Studio (version 3.5.0). 
 
Evaluation of humoral immune responses. For evaluation of in vivo T cell 
responses, WT and AAV8-reconstituted mice (46w post gene transfer, 49 
weeks of age) were immunized with ovalbumin (3x200 µg complexed with 
complete Freund’s adjuvant at Day 0, incomplete Freund’s adjuvant at day 14 
and LPS at day 28). Serum IgG levels were evaluated at time 0 and 6 weeks 
post immunization by enzyme-linked immunosorbent assay (ELISA). Serum 
anti-ZAP-70 antibodies were evaluated by ELISA at different time points post 
gene transfer. Briefly, 96 well plates (Nunc MaxiSorp, Thermo Scientific) were 
coated with recombinant ZAP-70 protein (0.5 μg/mL, Thermo Scientific), sera 
were added at 1:100 and 1:500 dilutions and a standard scale was generated 
by serial dilutions of an anti-ZAP-70 mAb (clone 1E7.2, Thermo Scientific). 
Responsiveness was monitored by horseradish peroxidase-conjugated goat 
anti-mouse IgG (Dako) and revealed using 2.2-3,3',5,5'-Tetramethylbenzidine 
(TMB, BD OptEIA, BD Biosciences). The threshold of positivity was determined 
by averaging the signal of 23 negative sera obtained from naive or AAV GFP 
injected mice + 2*SD. Serum anti-double stranded DNA (dsDNA), anti-
ribonucleoprotein (RNP) and SSA (Sjögren’s-syndrome-related antigen A) 
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were quantified by ELISA following the manufacturer’s instructions (Alpha 
Diagnostic International, San Antonio, TX).  
 
The presence of neutralizing antibody in serum samples was monitored as 
previously described10. Two hours prior to rAAV infection, a permissive cell line 
was infected with wild-type Adenovirus serotype 5. During this incubation time, 
a rAAV2/8 expressing the reporter gene LacZ (encoding beta-galactosidase) 
was incubated with serial dilutions of serum and the mix was added to the cell 
line. Infection was assessed using the luminescent β-galactosidase substrate 
(Tropix Galacto-Star kit, Thermo Scientific) at 48h. The neutralizing capacity of 
a given serum is expressed as the titer corresponding to the highest serum 
dilution at which more than 50% of maximal infection is inhibited. 
 
Screening for IgM and IgG reactivity against 123 autoantigens was performed 
using autoantibody arrays (UT Southwestern Medical Center, Genomic and 
Microarray Core Facility, Dallas, Texas) as previously described11, 12 and 
heatmaps were generated using R software.   
 
Statistical analyses 
Data were analyzed using GraphPad software version 5 and 8 (Graph Pad Prism, La 
Jolla, CA) and p values were calculated using unpaired t-tests, one-way ANOVA 
(Tukey’s multiple comparison test), and Mann-Whitney tests, as indicated. P values for 
comparisons of all conditions in the different figure panels are presented in the figure 
legends. 
 
Extended Figures 
Fig E1. Intrathymic AAV8-ZAP-70 gene transfer results in alterations in 
medulla area in ZAP-70-/- mice. A, Thymic medulla area was evaluated by 
keratin14 (K14) staining. Representative confocal images of thymic tissue 
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sections are presented in Figure 2. Quantification of the medullary area in mm2 
of thymus was quantified in the indicated conditions. Each point represents the 
quantification of individual medulla derived from 2-3 mice at the indicated time 
points and significance was determined by a 2-tailed unpaired t-test. ns, non-
significant; **, p<0.01; ****, p<0.0001. B, The absolute numbers of thymocytes 
in IT-AAV8-ZAP-70 transduced KO mice (n=11) were determined at 3 weeks 
post gene transfer as well as in age-matched WT and KO control mice (n=3-
10). Each point represents an individual mouse with horizontal lines showing 
means. Data between groups were not significantly different.     
 
Fig E2. Transient induction of a broad spectrum of IgM antibodies in ZAP-
70-/- mice following intrathymic AAV8 gene transfer. IgM autoantibody 
levels were evaluated in sera of ZAP-70-/- (KO) mice and following IT 
administration of either AAV8-GFP or AAV8-ZAP-70 vectors at the indicated 
time points.  IgM autoantibodies against 123 antigens were assessed by protein 
microarray. Heat maps showing autoantibody reactivity relative to levels in age-
matched WT mice are presented. 
 
Fig E3. High expression of Treg markers in IT: AAV8-ZAP-70-transduced 
mice. A, Cytokine levels in sera of WT and ZAP-70-/- mice treated by IT AAV8-
ZAP-70 gene transfer was evaluated at 3, 10, and 43 weeks post injection by 
cytokine bead array. Each point represents data from a single mouse and 
horizontal lines represent mean levels (pg/ml). Statistical significance was 
determined by a 2-tailed Mann-Whitney test and no groups exhibited significant 
differences.  B, Surface levels of CTLA4, GITR and CD39 on CD4+CD25Hi T 
cells from WT and IT:AAV8-ZAP-70-transduced KO mice were evaluated by  
flow cytometry and representative histograms are shown (top). Quantification 
of the mean fluorescence intensity (MFI) in T cells from individual mice are 
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presented and significance was assessed by an unpaired t-test (bottom). **, 
p<0.01; ****, p<0.0001   
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